Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly financial results for period ended June 30, 2026, announced August 6, 2026.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly financial results for period ended June 30, 2026, announced August 6, 2026
- Press release containing results furnished as Exhibit 99.1
- Disclosure not deemed filed under Exchange Act Section 18 or incorporated by reference without specific reference
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 LUCIDITY completed final visits in 78 participants; topline PBH data expected late August or early September 2026
- Positive results could support avexitide NDA submission and potential 2027 commercial launch
- Cash, equivalents and marketable securities $250.8M at June 30, supporting operations into 2028
- Q2 net loss $43.4M, or $0.39 per share, versus $41.4M, or $0.46 per share, in Q2 2025
- SG&A rose to $21.9M from $15.6M as Amylyx increased commercial preparation spending ahead of potential launch
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.